Characterization of community acquired pneumonia (CAP) with severe sepsis at diagnosis

B. Montull Veiga, R. Menéndez Villanueva, A. Torres, S. Reyes, R. Zalacaín, A. Capelastegui, J. Aspa, L. Borderías, J.J. Martín-Villasclaras, S. Bello, I. Alfageme, F. Rodríguez de Castro, J. Rello, L. Molinos, J. Ruiz-Manzano (Valencia, Barcelona, Xativa, Bilbao, Vizcaya, Madrid, Huesca, Malaga, Zaragoza, Sevilla, Las Palmas de Gran Canaria, Oviedo, Badalona, Spain)

Source: Annual Congress 2012 - Epidemiology: risk factors and prognosis in respiratory infections
Session: Epidemiology: risk factors and prognosis in respiratory infections
Session type: Poster Discussion
Number: 1735
Disease area: Respiratory infections

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
B. Montull Veiga, R. Menéndez Villanueva, A. Torres, S. Reyes, R. Zalacaín, A. Capelastegui, J. Aspa, L. Borderías, J.J. Martín-Villasclaras, S. Bello, I. Alfageme, F. Rodríguez de Castro, J. Rello, L. Molinos, J. Ruiz-Manzano (Valencia, Barcelona, Xativa, Bilbao, Vizcaya, Madrid, Huesca, Malaga, Zaragoza, Sevilla, Las Palmas de Gran Canaria, Oviedo, Badalona, Spain). Characterization of community acquired pneumonia (CAP) with severe sepsis at diagnosis. Eur Respir J 2012; 40: Suppl. 56, 1735

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Biomarkers and community acquired pneumonia (CAP) severity
Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity
Year: 2010

Biomarkers and community acquired pneumonia (CAP) severity
Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia
Year: 2011


Initial and persistent inflammatory response in treatment failure in community-acquired pneumonia
Source: Annual Congress 2007 - Prognostic laboratory tests in community-acquired pneumonia
Year: 2007


Incidence of severe sepsis as a cause of clinical failure in patients with community-acquired pneumonia (CAP)
Source: Eur Respir J 2007; 30: Suppl. 51, 42s
Year: 2007

Hyponatraemia in community acquired pneumonia (CAP) in childhood
Source: Eur Respir J 2003; 22: Suppl. 45, 318s
Year: 2003

Acute respiratory failure (ARF) and severe sepsis (SS) in community acquired pneumonia (CAP): different outcomes?
Source: Annual Congress 2009 - Impact of biomarkers in the management of community-acquired pneumonia
Year: 2009


Detection of liver function in patients with severe community-acquired pneumonia (CAP)
Source: Eur Respir J 2002; 20: Suppl. 38, 15s
Year: 2002

Factors related to obtain an etiological diagnosis in community acquired pneumonia (CAP)
Source: Annual Congress 2007 - Prognostic laboratory tests in community-acquired pneumonia
Year: 2007



Cardiac diseases in patients with community acquired pneumonia (CAP)
Source: Annual Congress 2012 - Epidemiology: risk factors and prognosis in respiratory infections
Year: 2012

Defining stability in pneumonia and the non-responding pneumonia
Source: Annual Congress 2005 - Outcome in severe pneumonia
Year: 2005

Biological markers in hospitalised patients with community acquired pneumonia (CAP)
Source: Annual Congress 2010 - The spectrum of lower respiratory tract infections: risk factors of poor outcome and diagnostic tools
Year: 2010

Hyperglycaemia in children with community acquired pneumonia (CAP)
Source: Eur Respir J 2003; 22: Suppl. 45, 318s
Year: 2003

I-ROAD could be efficient in predicting severity of community acquired pneumonia (CAP) or healthcare-associated-pneumonia(HCAP)
Source: Annual Congress 2010 - Healthcare-associated pneumonia: ventilator-associated pneumonia and pneumonia in hospitalised patients
Year: 2010

Management of severe community acquired pneumonia
Source: Virtual Congress 2020 – German programme 2020
Year: 2020


Effect of benzylpenicillin-ciprofloxacin vs. ceftriaxon-ciprofloxacin in treatment of massive pneumonia (CAP-community acquired pneumonia)
Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections
Year: 2011

An unbalanced inflammatory response on admission impacts clinical stability in hospitalized patients with community-acquired pneumonia (CAP)
Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia
Year: 2011


Community-acquired pneumonia
Source: Respipedia Article
Year: 2017

Comparison of pneumonia severity scoring methods in identification of severe community acquired pneumonia
Source: International Congress 2017 – CAP: severity scores, risk groups and biomarkers
Year: 2017

Clinical stability in patients with community- acquired pneumonia (CAP)
Source: Annual Congress 2011 - New aspects in prevention and treatment of community-acquired pneumonia and lower respiratory tract infections
Year: 2011

Japanese guidelines for the management of community-acquired pneumonia: differential diagnosis of atypical pneumonia and bacterial pneumonia
Source: Eur Respir J 2006; 28: Suppl. 50, 374s
Year: 2006